Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Drugmaker AstraZeneca said its Brilinta drug was approved in the US to reduce the risk of stroke to death in patients with acute ischemic stroke or high-risk transient ischaemic attack.
The approval by the US Food and Drug Administration (FDA) was based on positive results from the THALES Phase III trial that showed aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischaemic stroke or transient ischaemic attack.
At 8:29am: (LON:AZN) Astrazeneca PLC share price was -126.5p at 8402.5p